DEALS: Bausch & Lomb expands China operations


Bausch & Lomb expands China operations


DEALS

WHO

WITH

WHAT

SCOOP

Bausch & Lomb

Sino Biopharmaceutical

Buying 55% interest in Chinese ophthalmic unit

Bausch & Lomb expands its presence in the Chinese market.

Techne

Fortron Bio Science/BiosPacific

$20M buyout

Techne gains a developer and manufacturer of monoclonal and polyclonal antibodies, antigens and other biological reagents.

Qiagen

Nextal Biotechnology

$14.2M Buyout

Qiagen gains a provider of proprietary sample preparation tools which make protein crystallization more accessible.

Torrent Pharma

Pfizer

Generic division buyout

India's Torrent acquires Heumann Pharma Generics of Germany for an undisclosed amount.

Takara Bio

Becton, Dickinson and Company

Acquiring BD's Clontech division

Clontech develops, produces and markets biological products to the life science market.

Blairex Laboratories

Zila

Brand line sale, $10.3M

Blairex gains the Zilactin brand of OTC lip and oral care products.

Millipore

Microsafe

$9.3 million buyout

Millipore adds contract lab to its list of assets.

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.